RNA-based therapeutics have expanded rapidly, with ASO-based interventions targeting SOD1 in ALS (tofersen), tau in AD, and huntingtin in HD advancing to clinical testing (39, 40, 77). The gene discussed is MAPT; the disease is amyotrophic lateral sclerosis.